m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG01113)
| Name |
Bicalutamide
|
||||
|---|---|---|---|---|---|
| Synonyms |
Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
Click to Show/Hide
|
||||
| Status |
Approved
|
||||
| Structure |
 |
||||
| Formula |
C18H14F4N2O4S
|
||||
| InChI |
1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
|
||||
| InChIKey |
LKJPYSCBVHEWIU-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
| VARIDT Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Androgen receptor (AR)
ETS-related transcription factor Elf-3 (ELF3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Androgen receptor (AR) is a therapeutic target for Bicalutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Bicalutamide through regulating the expression of Androgen receptor (AR). | [1], [2] | ||
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Bicalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bicalutamide through regulating the expression of Breast cancer resistance protein (ABCG2). | [3], [4] | ||
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bicalutamide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bicalutamide through regulating the expression of P-glycoprotein 1 (ABCB1). | [4], [5] | ||
Methyltransferase-like 3 (METTL3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bicalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bicalutamide through regulating the expression of P-glycoprotein 1 (ABCB1). | [3], [4] | ||
References